Phixen S.A.S. (Cenexi), the wholly-owned step-down subsidiary of Gland Pharma Limited, has appointed a new Chief Executive Officer (President), for a duration of 1 year, effective 19th September 2023.

Jim McPherson (Coaching and Consulting) Limited (JMCL), a legal person, has been appointed as the new Chief Executive Officer (President) of Phixen S.A.S and Jim McPherson, as JMCL’s permanent representative, would be taking care of the functions as the new Chief Executive Officer (President) of the company

McPherson has been a pharmaceutical executive with over 30 years of leadership experience in branded and generic pharma companies. He brings expertise in strategy development and implementation, transformational change management, business development, supply chain management, and technical operations leadership.

Before taking a role at Phixen S.A.S, Jim held leadership positions at several companies, including Centrient Pharmaceuticals, Leo Pharmaceuticals, Sandoz, Xellia, and GSK.

McPherson holds a Bachelor of Science in Industrial Studies from Napier University in Edinburgh, United Kingdom, and a Master of Business Administration from Glasgow University in Glasgow, United Kingdom.

As the group makes strategic progress in achieving the goals at Cenexi, Jim's leadership will bring clarity, focus, and a solid client-centric mindset to the role.